FATE Fate Therapeutics, Inc.
XNAS
1.94
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
FATE
$1.94
—
What changed
Recent filings, trades and movesKey stats
$1.94
- 52-Week Range
- $0.95 – $3.23
- YTD
- +96.67%
- Straddle Price
- $2.95
- P/C Vol Ratio
- 2.34
- Market Cap
- $0.2B
- Open
- $1.87
- Day Range
- $1.85 – $2.00
- Volume
- 2,214,992
- Prev Close
- $1.83
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.98 |
| Cost of Equity (CAPM) | 15.79% (VRP-adj) |
| WACC | 15.84% |
| Volatility Risk Premium | +148.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +19.6% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -82.1% |
| Book / Price | 69.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -1627.8% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $2.24 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.02 |
| Bollinger Width / SMA20 | 21.9% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: INGN, KIDS, MYGN, PCRX
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
93%
20-Day Fair Value
≈ by Dec 8, 2026
$1.96
α +0.9%
rank 48%
conviction
63%
40-Day Fair Value
≈ by Jan 6, 2027
$2.02
α +4.2%
rank 51%
conviction
92%
60-Day Fair Value
≈ by Feb 4, 2027
$2.05
α +5.8%
rank 48%
conviction
93%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $2.64 | 25% | median 2.1× · 4 peers |
| Peer P/S | $0.08 | 25% | median 1.4× · 4 peers |
| Market Anchor (SMA50) | $2.24 | 51% | stability 40% (BB-width) |
| Options Expected (B-L 30d) | $1.75 | 0% | 5 strikes · skew +0.71 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.2B
- Employees
- 161
- List Date
- 2013-10-01
- CIK
- 0001434316
- Last Earnings
- Nov 5 after close · −1.1% vs ±39.2% expected
- Next Earnings
- ~Feb 25, 2027 (estimated)
- Headquarters
- San Diego, CA
- Homepage
- https://www.fatetherapeutics.com
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 1.06% | -31.14% | -41.40% | 66.94% | -27.37% | 20.64% | -1.88% |
| Feb | -3.69% | -15.96% | -3.92% | 4.88% | -11.81% | 20.33% | -1.70% |
| Mar | -14.66% | 12.64% | -6.40% | -5.17% | -23.29% | -20.00% | -9.48% |
| Apr | 6.69% | -30.88% | 4.48% | -44.21% | 69.07% | 0.81% | 0.99% |
| May | -10.00% | -22.41% | -20.60% | -10.02% | -2.42% | 85.62% | 3.36% |
| Jun | 19.78% | 9.50% | -6.11% | -10.63% | -13.85% | -1.46% | -0.46% |
| Jul | -12.19% | 21.44% | -14.32% | 63.50% | -3.51% | -20.84% | 5.68% |
| Aug | -13.90% | -12.98% | -36.78% | -24.80% | -2.80% | -4.40% | -15.94% |
| Sep | -21.29% | -17.09% | -24.56% | 1.45% | 22.33% | -2.47% | -6.94% |
| Oct | -9.58% | -7.72% | -5.73% | -29.25% | 8.00% | -9.57% | -8.97% |
| Nov | -4.76% | -0.81% | 29.02% | 30.45% | -9.52% | -3.48%* | 6.82% |
| Dec | 12.24% | -50.39% | 41.13% | -44.26% | -4.60% | -- | -9.18% |
| Total | -45.05% | -84.77% | -71.21% | -52.20% | -25.31% | 37.95% | -40.10% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.01
SMA 50: $2.23
SMA 200: $1.98
Current: $1.94
EMA 12: $2.00
EMA 26: $2.08
MACD: -0.0783 | Signal: -0.0055
BEARISH
ADX (14): 10.58
RANGE
+DI: 17.23
−DI: 24.81
Momentum Oscillators
RSI (14): 42.21
NEUTRAL
Stoch %K: 19.25
Stoch %D: 34.16
Williams %R: -69.05
Volume & Volatility
BB Upper: $2.22
BB Lower: $1.79
NEUTRAL
OBV: 98,862,084
Vol SMA 20: 1,347,259
Vol ROC: 51.57%
ATR: $0.14
True Range: $0.17
HV 20: 78.7%
HV 30: 70.7%
HV 60: 61.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before FATE’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 7/10)
Key Drivers:
- Strong technical momentum signals, including bullish MACD crossover
- Positive news sentiment from recent headlines focusing on the company's growth prospects and industry trends
- High volatility and beta indicate potential for increased trading activity
Primary Risks:
- Overbought RSI and stochastic indicators suggest potential near-term pullback
- High implied volatility may lead to increased option trading and market uncertainty
Investment Thesis: FATE stock is likely to continue its upward trend due to the company's growth prospects, positive industry trends, and strong technical momentum. However, investors should be cautious of potential near-term pullbacks and ensure proper risk management.
Recent News Sentiment Impact: The recent news headlines have had a significant bullish impact on the stock price, with an overall sentiment score of 4/5 (very positive).
Technical Analysis
Trend Direction:
- Short-term: Uptrend
- Medium-term: Uptrend
- Long-term: Range-bound
Support/Resistance Levels:
- Resistance: $2.82 (Bollinger Band upper)
- Support: $2.28 (Bollinger Band lower)
Momentum Signals:
- RSI interpretation: Neutral (40.85)
- MACD signal: Bullish crossover
- Bollinger Bands position: Squeeze
Volume Analysis:
- Volume SMA 20: 2068244.89
- On-Balance Volume (OBV): 72690421.60
- Volume Rate of Change: -58.14%
News & Sentiment Analysis
Recent Headlines Summary:
- Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies (GlobeNewswire Inc., 2026-06-10)
- Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (Benzinga, 2026-05-20)
- Scalable Biotech Manufacturing Unlocks a $14B Market (Benzinga, 2026-03-27)
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (Benzinga, 2026-03-03)
- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight (GlobeNewswire Inc., 2026-02-16)
- Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets (GlobeNewswire Inc., 2026-01-23)
Sentiment Assessment: Positive
Catalyst Identification:
- Earnings announcement date: Not available
- Product launches and regulatory changes: None noted in recent news headlines
Market Narrative:
- Recent news headlines have had a significant bullish impact on the stock price, aligning with the company's growth prospects and positive industry trends.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 1.96 (High risk relative to market)
- Volatility regime: High volatility
- Options market signals: IV rank 37.2% (Medium), put/call ratio 1.06 (Neutral)
Downside Protection:
- Support levels: $2.28 (Bollinger Band lower) and $2.12 (SMA 20)
- Risk management considerations: Investors should consider implementing stop-loss orders or position sizing to manage potential losses.
Market Context & Positioning
Sector Performance:
- FATE's sector, Biotechnology, has been performing relatively well in the recent past, with a positive return over the last quarter.
Institutional Activity:
- Institutional investors have been actively buying and selling FATE stock, with an average daily volume of 2068244.89 shares.
Correlation Analysis:
- FATE's correlation with the broader market (SPY) is relatively low at 0.26, indicating limited correlation.
Relative Valuation:
- FATE's current price-to-earnings ratio is slightly above its historical average, suggesting a potentially overvalued stock.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $2.82 (Bollinger Band upper)
- Support: $2.28 (Bollinger Band lower)
Breakout/Breakdown Levels:
- Breakout level: $3.12 (SMA 50)
- Breakdown level: $1.92 (SMA 200)
Time-Sensitive Catalysts:
- Earnings announcement date: Not available
- Product launches and regulatory changes: None noted in recent news headlines
Risk Management:
- Investors should consider implementing stop-loss orders or position sizing to manage potential losses.
Data Interpretation Notes
- RSI interpretation: Neutral (40.85)
- MACD signal: Bullish crossover
- Bollinger Bands position: Squeeze
- Beta: 1.96 (High risk relative to market)
News Impact Assessment
- Positive news headlines have had a significant bullish impact on the stock price.
- No negative or neutral news headlines were noted in recent headlines.
Risk Assessment Criteria
- High risk: Beta >1.5, high volatility, and negative news sentiment.
Generated
News
All FATE news →
Earnings History
22 of 22 under expected move
Avg Expected Move
60.15%
Avg Actual Move
5.89%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-24 | After-Close | 19.31% | 9.45% | 0.49x | Within |
| 2021-05-05 | After-Close | 17.26% | 1.52% | 0.09x | Within |
| 2021-08-04 | After-Close | 15.40% | 11.44% | 0.74x | Within |
| 2021-11-04 | After-Close | 12.07% | 2.97% | 0.25x | Within |
| 2022-02-28 | After-Close | 17.08% | 0.38% | 0.02x | Within |
| 2022-05-04 | After-Close | 14.66% | 11.40% | 0.78x | Within |
| 2022-08-03 | After-Close | 16.76% | 0.79% | 0.05x | Within |
| 2022-11-03 | After-Close | 14.14% | 2.01% | 0.14x | Within |
| 2023-05-03 | After-Close | 23.10% | 2.37% | 0.10x | Within |
| 2023-08-08 | After-Close | 31.16% | 3.68% | 0.12x | Within |
| 2023-11-08 | After-Close | 16.31% | 8.58% | 0.53x | Within |
| 2024-02-26 | After-Close | 25.47% | 7.34% | 0.29x | Within |
| 2024-08-13 | After-Close | 76.35% | 2.10% | 0.03x | Within |
| 2024-11-12 | Pre-Market | 22.46% | 7.03% | 0.31x | Within |
| 2025-03-05 | After-Close | 74.58% | 14.90% | 0.20x | Within |
| 2025-05-13 | Pre-Market | 28.04% | 6.54% | 0.23x | Within |
| 2025-08-12 | After-Close | 56.07% | 20.69% | 0.37x | Within |
| 2025-11-13 | Pre-Market | 728.37% | 4.59% | 0.01x | Within |
| 2026-02-26 | After-Close | 33.65% | 5.13% | 0.15x | Within |
| 2026-05-12 | After-Close | 14.44% | 5.11% | 0.35x | Within |
| 2026-08-11 | After-Close | 27.37% | 0.73% | 0.03x | Within |
| 2026-11-05 | After-Close | 39.19% | 0.81% | 0.02x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
FATE Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.95
7-DTE Move: $0.88
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 537
Put Volume: 1,257
P/C Volume: 2.341
BEARISH
Call OI: 5,173
Put OI: 1,209
P/C OI: 0.234
Total OI: 6,382
ATM Options Pricing
ATM Call: $2.50
ATM Put: $0.45
Call %: 128.9%
Put %: 23.2%
Chain Summary
Chain Volume: 1,794
Chain OI: 6,382
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 13th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
13%
vs own history
GEX tilt
-0.59
OI-weighted, today
Vanna tilt
-0.16
δ-sensitivity to IV
Charm tilt
+0.86
δ-decay vs time
Charm tilt +0.86: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.95Nov 9
Beta Analysis
Risk Metrics
Beta: 2.1657
Alpha: 70.93%
Correlation: 0.3339
R-Squared: 11.1%
Stock Volatility: 89.2%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own FATE
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $8.1M | #1177 of 3138 | +0.3% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $6.6M | #1878 of 3716 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $2.7M | #2616 of 6285 | +5.3% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.2M | #1432 of 1945 | +925.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
FATE Institutional Ownership (13F)
Filings for 2026-06-30 · 41 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 119,671,084 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$761.86K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $254.88K | 33.46% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $242.73K | 31.86% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $166.86K | 21.90% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $59.94K | 7.87% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $37.45K | 4.92% | 2026-09-30 |
4 filers$315.49K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $267.84K | 84.90% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $28.08K | 8.90% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $18.49K | 5.86% | 2026-09-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.08K | 0.34% | 2026-06-30 |
FATE Insider Trading (Form 4)
Latest: 2026-11-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-04 | Kamal Adawi | Chief Financial Officer | Sell (S) | −6,582 | $2.05 | -$13.5K | EDGAR |
| 2026-08-05 | Cindy Tahl | See Remarks | Sell (S) | −38,800 | $2.46 | -$95.4K | EDGAR |
| 2026-08-05 | Bahram Valamehr | President and CEO | Sell (S) | −43,947 | $2.46 | -$108.1K | EDGAR |
| 2026-06-15 | Matt Abernethy | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Robert S Epstein | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Shefali Agarwal | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Laura Hamill | Director | Grant (A) | +175,800 opt | — | EDGAR | |
| 2026-06-15 | William H Rastetter | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Jeremy Green | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Yuan Xu | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Karin Jooss | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-06-15 | Michael Stewart Lee | Director | Grant (A) | +87,900 opt | — | EDGAR | |
| 2026-05-21 | Bahram Valamehr | President and CEO | Sell (S) | −28,946 | $1.88 | -$54.5K | EDGAR |
| 2026-05-21 | Cindy Tahl | See Remarks | Sell (S) | −25,590 | $1.88 | -$48.1K | EDGAR |
| 2026-05-07 | Cindy Tahl | See Remarks | Exer (M) | +166,664 | $1.25 | $208.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
FATE Insider Holdings
12 insiders · @ $1.94
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jeremy Green | Director | 12,884,277 | $25.00M | $105.36M | 21 | 2026-06-15 |
| 2 | Bahram Valamehr | President and CEO | 591,815 | $1.15M | -$14.35M | 32 | 2026-08-05 |
| 3 | Cindy Tahl | See Remarks | 589,355 | $1.14M | -$28.74M | 41 | 2026-08-05 |
| 4 | William H Rastetter | Director | 495,603 | $961.5K | $1.50M | 17 | 2026-06-15 |
| 5 | Jerome Charles Bressi | See Remarks | 335,203 | $650.3K | -$9.3K | 2 | 2025-01-16 |
| 6 | John Mendlein | Director | 311,231 | $603.8K | -$338.1K | 16 | 2025-05-30 |
| 7 | Kamal Adawi | Chief Financial Officer | 93,418 | $181.2K | -$13.5K | 3 | 2026-11-04 |
| 8 | Robert S Epstein | Director | 36,331 | $70.5K | $0 | 14 | 2026-06-15 |
| 9 | Michael Stewart Lee | Director | 11,331 | $22.0K | $0 | 9 | 2026-06-15 |
| 10 | Shefali Agarwal | Director | 10,490 | $20.4K | -$36.8K | 11 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
FATE Board & Officers
As of SEC filings through Nov 4, 2026Directors 12
- William H Rastetter · since Sep 30, 2013
- Robert S Epstein · since Mar 14, 2014
- Michael Stewart Lee · since Jul 31, 2018
- Jeremy Green · listed since Aug 2018
- Redmile Group, LLC (entity) · listed since Aug 2018
- Karin Jooss · since Mar 14, 2019
- Shefali Agarwal · since Jul 15, 2019
- Yuan Xu · since Aug 3, 2021
- Bahram Valamehr · listed since Jan 2025
- Matt Abernethy · since May 29, 2025
- RedCo II Master Fund, L.P. (entity) · since Jul 2, 2025
- Laura Hamill · since Jun 12, 2026
Officers 3
- Bahram Valamehr · President and CEO · listed since Jan 2025
- Kamal Adawi · Chief Financial Officer · since Oct 20, 2025
- Cindy Tahl · Chief Legal and Compliance Officer · listed since Aug 2025
10% owners 3
- Jeremy Green · listed since Aug 2018
- RedCo II Master Fund, L.P. (entity) · since Jul 2, 2025
- Redmile Group, LLC (entity) · since Dec 15, 2017
Changes in the last 10 years (36)
| Jun 12, 2026 | Laura Hamill became a director |
| Oct 20, 2025 | Kamal Adawi became Chief Financial Officer |
| Oct 10, 2025 | The company announced the departure of Neelufar Mozaffarian from the board in an SEC filing |
| Oct 10, 2025 | The company announced the departure of John Mendlein from the board in an SEC filing |
| Aug 5, 2025 | Cindy Tahl listed as Chief Legal and Compliance Officer (previously Chief Legal & Compliance Officer and Secretary) in SEC filings |
| Jul 2, 2025 | RedCo II Master Fund, L.P. became a director |
| Jul 2, 2025 | RedCo II Master Fund, L.P. became a 10% owner |
| May 29, 2025 | Matt Abernethy became a director |
| Jan 13, 2025 | Cindy Tahl listed as Chief Legal & Compliance Officer and Secretary (previously General Counsel and Secretary) in SEC filings |
| Jan 13, 2025 | Bahram Valamehr listed as President and CEO (previously Chief R&D Officer) in SEC filings |
| Jan 13, 2025 | Bahram Valamehr first listed as a director in an SEC filing |
| Nov 27, 2024 | The company announced the departure of J Scott Wolchko from the board in an SEC filing |
| Nov 27, 2024 | The company announced the departure of J Scott Wolchko as President and CEO in an SEC filing |
| Aug 14, 2024 | Jerome Charles Bressi became Chief Regulatory and Quality Officer |
| Jul 29, 2024 | Neelufar Mozaffarian became a director |
| May 30, 2024 | The company announced the departure of Edward J Dulac III as Chief Financial Officer in an SEC filing |
| Jun 8, 2023 | The company announced the departure of Yu-Waye Chu as Chief Medical Officer in an SEC filing |
| Jan 3, 2023 | The company announced the departure of Mark Plavsic as Chief Technical Officer in an SEC filing |
| Jun 27, 2022 | Brian T. Powl became Chief Commercial Officer |
| Jan 27, 2022 | Yu-Waye Chu listed as Chief Medical Officer (previously Senior VP Clinical Development) in SEC filings |
| Nov 22, 2021 | Bahram Valamehr listed as Chief R&D Officer (previously Chief Development Officer) in SEC filings |
| Aug 3, 2021 | Yuan Xu became a director |
| Jun 14, 2021 | Mark Plavsic became Chief Technical Officer |
| Mar 24, 2021 | Yu-Waye Chu became Senior VP Clinical Development |
| Aug 17, 2020 | Edward J Dulac III became Chief Financial Officer |
| May 1, 2020 | Robert Hershberg became a director |
| Jul 15, 2019 | Shefali Agarwal became a director |
| Mar 14, 2019 | Karin Jooss became a director |
| Aug 2, 2018 | Redmile Group, LLC first listed as a director in an SEC filing |
| Aug 2, 2018 | Jeremy Green no longer listed as an officer in SEC filings |
| Aug 2, 2018 | Jeremy Green first listed as a director in an SEC filing |
| Aug 2, 2018 | Jeremy Green first listed as a 10% owner in an SEC filing |
| Jul 31, 2018 | Michael Stewart Lee became a director |
| Jul 31, 2018 | Bahram Valamehr became Chief Development Officer |
| Dec 15, 2017 | Redmile Group, LLC became a 10% owner |
| Dec 15, 2017 | Jeremy Green became an officer |
Not reported recently (9)
- Jerome Charles Bressi · Last reported as Chief Regulatory and Quality Officer in an SEC filing dated Jan 16, 2025
- Timothy Coughlin · Last reported as a director in an SEC filing dated Jun 11, 2024
- Brian T. Powl · Last reported as Chief Commercial Officer in an SEC filing dated Jul 6, 2023
- Robert Hershberg · Last reported as a director in an SEC filing dated Jun 7, 2023
- Daniel D Shoemaker · Last reported as Chief Scientific Officer in an SEC filing dated Mar 9, 2021
- Amir Nashat · Last reported as a director in an SEC filing dated Aug 2, 2019
- Stewart Abbot · Last reported as Chief Development Officer in an SEC filing dated May 16, 2018
- Chris Storgard · Last reported as Chief Medical Officer in an SEC filing dated Jan 17, 2018
- Mark J Enyedy · Last reported as a director in an SEC filing dated May 4, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
FATE Proposed Insider Sales (Form 144)
Latest: 2026-11-03
? Form 144 Guide
Last 30d:
1 filing
· $14K notice value
· Last 90d:
1 filing
· $14K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Adawi Kamal (1, $14K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-03 | Adawi Kamal | Officer | 6,582 | $13.5K | 2026-11-03 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-04 | TAHL CINDY | Officer | 38,800 | $95.4K | 2026-08-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-04 | Valamehr Bahram | Officer, Director | 43,947 | $108.1K | 2026-08-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-20 | Valamehr Bahram | Officer, Director | 28,946 | $54.5K | 2026-05-20 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-20 | TAHL CINDY | Officer | 25,590 | $48.1K | 2026-05-20 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-01-09 | TAHL CINDY | Officer | 10,589 | $11.3K | 2026-01-09 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-01-09 | Valamehr Bahram | Officer, Director | 5,190 | $5.6K | 2026-01-09 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-29 | MENDLEIN JOHN | Former Director | 38,428 | $38.9K | 2025-12-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-08-04 | TAHL CINDY | Officer | 9,037 | $9.6K | 2025-08-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-08-04 | Valamehr Bahram | Officer, Director | 14,466 | $15.4K | 2025-08-04 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
14 ETFs hold FATE
14 shown · $14.57M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $7.6M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.8M | — | 2026-09-30 |
| 3 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.2M | — | 2026-08-31 |
| 4 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $677,294 | — | 2026-09-30 |
| 5 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.05% | $642,634 | $1.2B | 2026-11-06 |
| 6 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $558,708 | — | 2026-07-31 |
| 7 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $294,894 | $3.2B | 2026-11-05 |
| 8 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $249,903 | — | 2026-08-31 |
| 9 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $211,183 | — | 2026-11-05 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $123,856 | — | 2026-11-05 |
| 11 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.46% | $91,148 | — | 2026-11-05 |
| 12 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $69,775 | — | 2026-11-05 |
| 13 | DFAU Dimensional US Core Equity Market ETF | Dimensional | 0.00% | $29,256 | $12.6B | 2026-11-05 |
| 14 | DFUS Dimensional US Equity Market ETF | Dimensional | 0.00% | $11,555 | $20.9B | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.05
TTM Revenue
$6.49M
TTM Net Income
$-126.00M
TTM Op. Cash Flow
$-101.94M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $2.08M | $-30.16M | $-0.25 | $-23.43M |
| Q1 '26 | 2026-03-31 | $1.30M | $-31.21M | $-0.26 | $-30.82M |
| Q4 '25 | 2025-12-31 | $1.37M | $-32.37M | $-0.27 | $-23.31M |
| Q3 '25 | 2025-09-30 | $1.74M | $-32.25M | $-0.27 | $-24.37M |
| Q2 '25 | 2025-06-30 | $1.91M | $-34.07M | $-0.29 | $-24.59M |
| Q1 '25 | 2025-03-31 | $1.63M | $-37.62M | $-0.32 | $-33.81M |
| Q4 '24 | 2024-12-31 | $1.86M | $-52.15M | $-0.45 | $-27.80M |
| Q3 '24 | 2024-09-30 | $3.07M | $-47.68M | $-0.40 | $-29.42M |
| Q2 '24 | 2024-06-30 | $6.77M | $-38.43M | $-0.33 | $-32.31M |
| Q1 '24 | 2024-03-31 | $1.93M | $-48.00M | $-0.47 | $-33.35M |
| Q4 '23 | 2023-12-31 | $1.68M | $-44.12M | $-0.45 | $-36.64M |
| Q3 '23 | 2023-09-30 | $1.94M | $-45.17M | $-0.46 | $-38.27M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.51
P/S
35.77
EV/EBITDA
—
EV/Sales
30.77
ROE
-82.1%
ROA
-48.4%
Div Yield
0.00%
FCF Yield
-43.91%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$232.16M
as of 2026-11-09
FATE vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ATRC AtriCure, Inc. | $3.0B | 275.1 | +13.9% | +47.1% | 23 |
| XNCR Xencor, Inc. | $2.7B | — | −28.6% | +158.6% | 40 |
| PCRX Pacira BioSciences, Inc. Common Stock | $1.5B | 104.2 | +5.7% | +49.1% | 1 |
| SIBN SI-BONE, Inc. Common Stock | $1.1B | — | +14.0% | +29.4% | 41 |
| KIDS OrthoPediatrics Corp. Common Stock | $829M | — | +16.1% | +93.6% | 13 |
| MYGN Myriad Genetics Inc | $564M | — | −3.2% | −6.5% | 39 |
| DTIL Precision BioSciences, Inc. Common Stock | $296M | — | +4802.1% | +136.1% | 20 |
| FATE Fate Therapeutics, Inc. | $223M | — | −23.4% | +96.7% | 31 |
| INGN Inogen Inc | $160M | — | +3.4% | −7.8% | 19 |
| Peer median | $961M | 189.7 | +9.8% | +48.1% | 22 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
10.62M
SI % of Float
10.39%
Days to Cover
8.73
Short Vol Ratio
54.3%
Free Float
102.24M
Float %
85.3%
Short interest 2026-10-15 • Short volume 2026-11-09 • Float 2026-08-14